BioTuesdays

Category - Markets

scPharmaceuticals
Markets

Leerink cuts scPharma to MP; PT to $5 from $12

Leerink downgraded scPharmaceuticals (NASDAQ:SCPH) to “market perform” from “outperform” and slashed its price target to $5 from $12 after the company inked a deal to use West Pharmaceuticals’ SmartDose on-body drug...

January 30, 2019
Evolus
Markets

Stifel starts Evolus at buy; PT $27

Stifel launched coverage of Evolus (NASDAQ:EOLS) with a “buy” rating and 12-month price target of $27. The stock closed at $14.99 on Jan. 28. “Evolus’ success hinges on the potential for Jeuveauto serve as an...

January 29, 2019
Revance
Markets

Stifel starts Revance Therapeutics at buy; PT $50

Stifel initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $50 target price. The stock closed at $17 on Jan. 28. Revance’s Daxi product represents “one of the first truly novel neurotoxin...

January 29, 2019
IsoRay
Markets

HCW assumes coverage of IsoRay at buy; PT 70 cents

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay (NYSE American:ISR) with a “buy” rating and price target of 70 cents, saying the company is “at an inflection point of sustainable revenue growth...

January 28, 2019
AzurRx BioPharma
Markets

Roth starts AzurRx BioPharma at buy; PT $10.50

Roth Capital Partners launched coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and price target of $10.50. The stock closed at $2.25 on Jan. 25. AzurRx is developing non-systemic, recombinant enzyme...

January 28, 2019
Bellerophon Therapeutics
Markets

Maxim starts Bellerophon Therapeutics at buy; PT $3

Maxim Group initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $3 price target. The stock closed at 67 cents on Jan. 23. Bellerophon’s lead product is the INOpulse delivery system of...

January 24, 2019
CannTrust Holdings
Markets

Paradigm starts CannTrust Holdings at buy; PT $18

Paradigm Capital launched coverage of CannTrust Holdings (TSX:TRST) with a “buy” rating and $18 price target. The stock closed at $8.35 on Jan.18. “CannTrust brings to the cannabis space a practice of professionalism...

January 18, 2019
Markets

HCW ups Aeterna Zentaris PT to $5.50 from $3

H.C. Wainwright raised its price target for Aeterna Zentaris (NASDAQ, TSX:AEZS) to $5.50 from $3 after its Macrilen agent for adult growth hormone deficiency (AGHD) was approved for sale in the EU. The stock closed at...

January 17, 2019